{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T14:52:31Z","timestamp":1789138351356,"version":"build-2803163510"},"reference-count":31,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018731","name":"Jiangsu Hengrui Pharmaceuticals Co., Ltd","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100018731","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Background: Remimazolam tosilate is a novel, ultra-short-acting benzodiazepine. To address the unmet clinical need for safe and controllable general anesthetic options in children and adolescents, both top-down (i.e., population pharmacokinetics\u2014PopPK) and bottom-up (i.e., physiologically based PK\u2014PBPK) modeling approaches were combined to leverage their respective strengths for dose selection in children and adolescents aged 3\u201318 years. Methods: Pooled PK data from adult studies were used to develop and verify the adult PopPK and PBPK models. The PopPK model included allometric scaling to describe body weight effects, while the PBPK modeling incorporated the age-dependent physiological and metabolic ontogeny. Potential covariates and intrinsic factors influencing remimazolam exposure were assessed. Both models were then applied to simulate PK and derive exposure metrics in 3\u201318-year-old children and adolescents. The predictions from both approaches were used to support pediatric dose selection using an adult-matching exposure approach. Results: The PopPK and PBPK model simulations yielded consistent exposure predictions and converged on the same recommended dosing regimens for the pediatric population, providing mutual confirmation of model reliability. Both models indicated that the proposed regimens of remimazolam would achieve systemic exposures in children and adolescents (3\u201318 years) comparable to those in adults receiving an induction dose of 0.3 mg\/kg followed by maintenance infusions of 1.0 or 3.0 mg\/kg\/h. Two pediatric dosing regimens were recommended: 1. Lower dose group: induction 0.2 mg\/kg, initial maintenance 1.0 mg\/kg\/h, titratable as needed, with a maximum rate of 3.0 mg\/kg\/h (up to 4.0 mg\/kg\/h for individuals \u2264 30 kg). 2. Higher dose group: induction 0.3 mg\/kg, initial maintenance 2.0 mg\/kg\/h, titratable as needed, with a maximum rate of 3.0 mg\/kg\/h (up to 4.0 mg\/kg\/h for individuals \u2264 30 kg). The model-informed dosing regimens have received regulatory approval from the Center for Drug Evaluation (CDE) in China and are currently being evaluated in an ongoing clinical trial. Conclusions: The integrated PopPK\u2013PBPK approach supports evidence-based dosing recommendations of remimazolam for general anesthesia in children and adolescents aged 3\u201318 years and provides a reference for dose selection in future clinical studies.<\/jats:p>","DOI":"10.3390\/pharmaceutics18030315","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T14:55:01Z","timestamp":1772463301000},"page":"315","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Dose Recommendation of Remimazolam Tosilate for General Anesthesia in Children and Adolescents: Synergistic Combination of PopPK and PBPK Approaches"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6644-9818","authenticated-orcid":false,"given":"Qiong-Yue","family":"Liang","sequence":"first","affiliation":[{"name":"Jiangsu Hengrui Pharmaceuticals Co., Ltd., Lianyungang 222006, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Hui","family":"Hu","sequence":"additional","affiliation":[{"name":"Jiangsu Hengrui Pharmaceuticals Co., Ltd., Lianyungang 222006, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3333-2979","authenticated-orcid":false,"given":"Nassim","family":"Djebli","sequence":"additional","affiliation":[{"name":"Jiangsu Hengrui Pharmaceuticals Co., Ltd., Lianyungang 222006, China"},{"name":"Luzsana Biotechnology Europe AG,  4051 Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-Yuan","family":"Huang","sequence":"additional","affiliation":[{"name":"Jiangsu Hengrui Pharmaceuticals Co., Ltd., Lianyungang 222006, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Jiang","sequence":"additional","affiliation":[{"name":"Jiangsu Hengrui Pharmaceuticals Co., Ltd., Lianyungang 222006, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"257","DOI":"10.5114\/ait\/210611","article-title":"Remimazolam: A comprehensive review","volume":"57","author":"Kapica","year":"2025","journal-title":"Anaesthesiol. Intensive Ther."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.17085\/apm.21115","article-title":"Remimazolam: Pharmacological characteristics and clinical applications in anesthesiology","volume":"17","author":"Kim","year":"2022","journal-title":"Anesth. Pain Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/ibra.12163","article-title":"Efficacy and safety of remimazolam versus propofol for intraoperative sedation during regional anesthesia: A phase II, multicenter, randomized, active-controlled, single-blind clinical trial","volume":"10","author":"Li","year":"2024","journal-title":"Ibrain"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.2147\/DDDT.S186759","article-title":"Metabolism of remimazolam in primary human hepatocytes during continuous long-term infusion in a 3-D bioreactor system","volume":"13","author":"Freyer","year":"2019","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1124\/dmd.115.068957","article-title":"Age-Dependent Human Hepatic Carboxylesterase 1 (CES1) and Carboxylesterase 2 (CES2) Postnatal Ontogeny","volume":"44","author":"Hines","year":"2016","journal-title":"Drug Metab. Dispos."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1124\/dmd.116.072652","article-title":"Age-Dependent Absolute Abundance of Hepatic Carboxylesterases (CES1 and CES2) by LC-MS\/MS Proteomics: Application to PBPK Modeling of Oseltamivir In Vivo Pharmacokinetics in Infants","volume":"45","author":"Boberg","year":"2017","journal-title":"Drug Metab. Dispos."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Chen, Q., Wang, L., Zeng, Q., Cui, H., Guo, S., Xiang, F., and Mo, Y. (2025). Remimazolam in pediatric anesthesia: A systematic review for clinical decision-making. Front. Pediatr., 13.","DOI":"10.3389\/fped.2025.1662752"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1016\/j.bja.2025.03.010","article-title":"The promise of precision: Exploring the role of remimazolam in paediatric anaesthesia","volume":"134","author":"Hansen","year":"2025","journal-title":"Br. J. Anaesth."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1002\/psp4.12446","article-title":"Application of Physiologically-Based and Population Pharmacokinetic Modeling for Dose Finding and Confirmation During the Pediatric Development of Moxifloxacin","volume":"8","author":"Willmann","year":"2019","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1002\/psp4.12688","article-title":"Population pharmacokinetic analysis of rivaroxaban in children and comparison to prospective physiologically-based pharmacokinetic predictions","volume":"10","author":"Willmann","year":"2021","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/psp4.13282","article-title":"MDMA pharmacokinetics: A population and physiologically based pharmacokinetics model-informed analysis","volume":"14","author":"Huestis","year":"2024","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1002\/psp4.70020","article-title":"Middle-Out Physiologically Based Pharmacokinetic Modeling to Support Pediatric Dosing Recommendation for Alectinib","volume":"14","author":"Guerini","year":"2025","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Zhou, Y., Hu, P., Huang, Y., Sang, N., Song, K., Wang, H., Wen, J., Jiang, J., and Chen, X. (2018). Population Pharmacokinetic\/Pharmacodynamic Model-Guided Dosing Optimization of a Novel Sedative HR7056 in Chinese Healthy Subjects. Front. Pharmacol., 9.","DOI":"10.3389\/fphar.2018.01316"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1097\/ALN.0000000000003103","article-title":"Pharmacokinetics and pharmacodynamics of remimazolam (CNS 7056) after continuous infusion in healthy male volunteers: Part I pharmacokinetics and clinical pharmacodynamics","volume":"132","author":"Schuttler","year":"2020","journal-title":"Anesthesiololgy"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1213\/ANE.0b013e318241f68a","article-title":"A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part II. Population pharmacokinetic and pharmacodynamic modeling and simulation","volume":"115","author":"Wiltshire","year":"2012","journal-title":"Anesth. Analg."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"109899","DOI":"10.1016\/j.jclinane.2020.109899","article-title":"Population pharmacokinetic\/pharmacodynamic modeling for remimazolam in the induction and maintenance of general anesthesia in healthy subjects and in surgical subjects","volume":"66","author":"Zhou","year":"2020","journal-title":"J. Clin. Anesth."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/cts.12875","article-title":"Population Pharmacokinetics of Remimazolam in Procedural Sedation With Nonhomogeneously Mixed Arterial and Venous Concentrations","volume":"14","author":"Zhou","year":"2020","journal-title":"Clin. Transl. Sci."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jchromb.2014.11.022","article-title":"Simultaneous determination of remimazolam and its carboxylic acid metabolite in human plasma using ultra-performance liquid chromatography\u2013tandem mass spectrometry","volume":"976\u2013977","author":"Zhou","year":"2015","journal-title":"J. Chromatogr. B"},{"key":"ref_19","unstructured":"(2025, February 20). DrugBank. Remimazolam: Uses, Interactions, Mechanism of Action. Available online: https:\/\/go.drugbank.com\/drugs\/DB12404."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Luo, X., Zhang, Z., Mu, R., Hu, G., Liu, L., and Liu, X. (2024). Simultaneously Predicting the Pharmacokinetics of CES1-Metabolized Drugs and Their Metabolites Using Physiologically Based Pharmacokinetic Model in Cirrhosis Subjects. Pharmaceutics, 16.","DOI":"10.3390\/pharmaceutics16020234"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.bja.2023.08.019","article-title":"Pharmacokinetics of remimazolam after intravenous infusion in anaesthetised children","volume":"131","author":"Gao","year":"2023","journal-title":"Br. J. Anaesth."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.bja.2021.05.027","article-title":"Pharmacokinetic properties of remimazolam in subjects with hepatic or renal impairment","volume":"127","author":"Colin","year":"2021","journal-title":"Br. J. Anaesth."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1681\/ASN.2006040368","article-title":"Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease","volume":"17","author":"Ma","year":"2006","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Kimoto, Y., Hirano, T., Kuratani, N., Cavanaugh, D., and Mason, K.P. (2023). Remimazolam as an Adjunct to General Anesthesia in Children: Adverse Events and Outcomes in a Large Cohort of 418 Cases. J. Clin. Med., 12.","DOI":"10.3390\/jcm12123930"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/anae.16475","article-title":"Safety and efficacy of remimazolam tosilate for general anaesthesia in paediatric patients undergoing elective surgery: A multicentre, randomised, single-blind, controlled trial","volume":"80","author":"Fang","year":"2024","journal-title":"Anaesthesia"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Chen, J., Wang, X., Chen, D., Liu, X., Peng, K., Tang, R., Hu, L., Wang, Y., Bai, Y., and Chang, L. (2025). Population pharmacokinetic analysis of remimazolam after continuous infusion for sedation in critically ill patients. Front. Pharmacol., 16.","DOI":"10.3389\/fphar.2025.1526266"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1007\/s40262-025-01548-7","article-title":"Clinical Pharmacokinetics and Pharmacodynamics of Remimazolam","volume":"64","author":"Eleveld","year":"2025","journal-title":"Clin. Pharmacokinet."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s00540-022-03079-y","article-title":"A population pharmacokinetic model of remimazolam for general anesthesia and consideration of remimazolam dose in clinical practice","volume":"36","author":"Masui","year":"2022","journal-title":"J. Anesth."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1093\/toxsci\/kfz211","article-title":"Development and Application of a Life-Stage Physiologically Based Pharmacokinetic (PBPK) Model to the Assessment of Internal Dose of Pyrethroids in Humans","volume":"173","author":"Mallick","year":"2019","journal-title":"Toxicol. Sci."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.bcp.2008.10.005","article-title":"Human carboxylesterases HCE1 and HCE2: Ontogenic expression, inter-individual variability and differential hydrolysis of oseltamivir, aspirin, deltamethrin and permethrin","volume":"77","author":"Yang","year":"2009","journal-title":"Biochem. Pharmacol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Fang, Y.-B., Wang, C.-Y., Gao, Y.-Q., Cai, Y.-H., Chen, J., Zhang, X.-L., Dong, L.-Q., Shang-Guan, W.-N., and Liu, H.-C. (2023). The safety and efficacy of remimazolam tosylate for induction and maintenance of general anesthesia in pediatric patients undergoing elective surgery: Study protocol for a multicenter, randomized, single-blind, positive-controlled clinical trial. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1090608"}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/18\/3\/315\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T05:24:15Z","timestamp":1772515455000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/18\/3\/315"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,1]]},"references-count":31,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["pharmaceutics18030315"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics18030315","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,1]]}}}